This is the fourth orphan drug we’ve licensed-in and it once again demonstrates our dedication to rare diseases. .. Abiogen Pharma, Lee’s Pharma sign deal to market Neridronic Acid Abiogen Pharma S.p.A. Under the term of the agreement, Abiogen Pharma S.p.A. Neridronate is the just therapeutic agent approved in the world for such orphan illnesses: OI and CRPS . Neridronate showed superior safety profile in long-term use and is definitely tolerated by adults and pediatric population highly. It is the just bisphosphonate indicated for use in kids and neonates. Dr. Massimo Di Martino, President & CEO of Abiogen Pharma stated: I am happy to discover that Neridronate could cross political and geographic barriers to benefit the individuals.The system is used at hundreds of hospitals and institutions all over the world.. Adding azithromycin to usual daily treatment designed for COPD decreases acute exacerbations by 27 percent Richard Casaburi, Ph.D., M.D., principal investigator at Los Angeles Biomedical Research Institute , is normally co-author of a recent study that should help improve the condition for the millions of individuals who suffer from chronic obstructive pulmonary disease, better referred to as COPD. The results of the analysis reveal that adding a common antibiotic – azithromycin – to the most common daily treatment for COPD decreased the occurrence of severe exacerbations by 27 percent and tended to improve the quality of existence for COPD patients.